Preliminary findings for pegilodecakin plus immune checkpoint inhibition suggest that the combination is tolerable and shows clinical activity.
Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months.
In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.
In AFT-30, increased frequency of PSA screening for localized prostate cancer did not boost survival, regardless of primary treatment or disease risk.
Tumor gene expression testing identifies women with certain early-stage breast cancers who can safely skip chemotherapy.
Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC.
For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib.
OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.
Pembrolizumab has shown activity against some lung cancer metastases in the brain, but responses can be discordant with extracranial tumor responses.
Obese patients survived longer during immune checkpoint blockade for metastatic lung cancer compared with underweight patients and those who lost weight during treatment.